Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors

Gragert, 2014, HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry, N Engl J Med, 371, 339, 10.1056/NEJMsa1311707

Beatty, 1985, Marrow transplantation from related donors other than HLA-identical siblings, N Engl J Med, 313, 765, 10.1056/NEJM198509263131301

Szydlo, 1997, Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J Clin Oncol, 15, 1767, 10.1200/JCO.1997.15.5.1767

Aversa, 2005, Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse, J Clin Oncol, 23, 3447, 10.1200/JCO.2005.09.117

Luznik, 2008, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 14, 641, 10.1016/j.bbmt.2008.03.005

Brunstein, 2011, Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts, Blood, 118, 282, 10.1182/blood-2011-03-344853

Grosso, 2011, A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing, Blood, 118, 4732, 10.1182/blood-2011-07-365338

Raiola, 2013, Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning, Biol Blood Marrow Transplant, 19, 117, 10.1016/j.bbmt.2012.08.014

Solomon, 2012, Biol Blood Marrow Transplant, 18, 1859, 10.1016/j.bbmt.2012.06.019

Zaucha, 2001, Blood, 98, 3221, 10.1182/blood.V98.12.3221

Mohty, 2003, Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation, Leukemia, 17, 869, 10.1038/sj.leu.2402909

Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825

Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004

Armand, 2014, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, 123, 3664, 10.1182/blood-2014-01-552984

O'Donnell, 2002, Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 8, 377, 10.1053/bbmt.2002.v8.pm12171484

Aoudjhane, 2005, Leukemia, 19, 2304, 10.1038/sj.leu.2403967

Mohty, 2010, Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, 116, 4439, 10.1182/blood-2010-02-266551

Ringdén, 2009, Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia, J Clin Oncol, 27, 4570, 10.1200/JCO.2008.20.9692

Shimoni, 2006, Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity, Leukemia, 20, 322, 10.1038/sj.leu.2404037

Zhang, 2012, Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials, Leuk Res, 36, 431, 10.1016/j.leukres.2011.10.016

2005, Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials, J Clin Oncol, 23, 5074, 10.1200/JCO.2005.09.020

Chang, 2012, Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials, Ann Hematol, 91, 427, 10.1007/s00277-011-1299-8

Nagler, 2013, J Clin Oncol, 31, 3549, 10.1200/JCO.2013.48.8114

Copelan, 2013, Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI, Blood, 122, 3863, 10.1182/blood-2013-07-514448

Ringden, 1999, Blood, 93, 2196, 10.1182/blood.V93.7.2196

Litzow, 2002, Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission, Br J Haematol, 119, 1115, 10.1046/j.1365-2141.2002.03973.x

Grosso, 2015, A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease, Biol Blood Marrow Transplant, 21, 646, 10.1016/j.bbmt.2014.12.019

Symons, 2015, Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies, Biol Blood Marrow Transplant, 21, S29, 10.1016/j.bbmt.2014.11.019

Kastan, 1990, Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells, Blood, 75, 1947, 10.1182/blood.V75.10.1947.1947

Yaghobi, 2009, The role of different risk factors in clinical presentation of hemorrhagic cystitis in hematopoietic stem cell transplant recipients, Transplant Proc, 41, 2900, 10.1016/j.transproceed.2009.07.060

Trotman, 1999, Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration, Bone Marrow Transplant, 23, 797, 10.1038/sj.bmt.1701644

Silva Lde, 2010, Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type, Haematologica, 95, 1183, 10.3324/haematol.2009.016758

Seber, 1999, Risk factors for severe hemorrhagic cystitis following BMT, Bone Marrow Transplant, 23, 35, 10.1038/sj.bmt.1701523

Ogawa, 2006, Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning, Biol Blood Marrow Transplant, 12, 1073, 10.1016/j.bbmt.2006.06.007

Lu, 2006, Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, Blood, 107, 3065, 10.1182/blood-2005-05-2146

Kroger, 2001, Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients, Bone Marrow Transplant, 27, 349, 10.1038/sj.bmt.1702802

Tiercy, 2012, Unrelated hematopoietic stem cell donor matching probability and search algorithm, Bone Marrow Res, 2012, 695018, 10.1155/2012/695018

Rambaldi, 2012, Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients, Leukemia, 26, 1779, 10.1038/leu.2012.55

Heemskerk, 2005, How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!, Bone Marrow Transplant, 35, 645, 10.1038/sj.bmt.1704865

van Agthoven, 2002, Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia, Bone Marrow Transplant, 30, 243, 10.1038/sj.bmt.1703641

Frassoni, 2000, Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation, Lancet, 355, 1393, 10.1016/S0140-6736(00)02137-1

Craddock, 2011, Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia, Leukemia, 25, 808, 10.1038/leu.2011.13

Saito, 2008, Costs of allogeneic hematopoietic cell transplantation with high-dose regimens, Biol Blood Marrow Transplant, 14, 197, 10.1016/j.bbmt.2007.10.010

Khera, 2012, Economics of hematopoietic cell transplantation, Blood, 120, 1545, 10.1182/blood-2012-05-426783

Matthes-Martin, 2012, Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable, Biol Blood Marrow Transplant, 18, 1533, 10.1016/j.bbmt.2012.04.002